ABT

Abbott Laboratories 10-Q Summary: Period Ended September 30, 2004

Business Context and Reporting Period

This is a quarterly report (Form 10-Q) for Abbott Laboratories for the three and nine months ended September 30, 2004. The reporting period is significantly impacted by the April 30, 2004, spin-off of Hospira, Inc., Abbott's hospital products business. Results for the nine months ended September 30, 2004, include only four months of Hospira operations, which are now classified as discontinued operations. The company reorganized its segments effective January 1, 2004, to reflect the spin-off and internal restructuring.

Key Financial Metrics

Margins: Gross profit margin for the nine months ended September 30, 2004, was 55.4%, compared to 55.0% in the prior year period. The effective tax rate for the nine months was 25.9%.

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 10.2% for the quarter and 13.3% for the nine months compared to 2003. Growth was driven by unit volume, the weaker U.S. dollar (contributing 1.8% to quarterly sales and 3.5% to nine-month sales), and acquisitions.
• Acquisitions: Significant cash outflows for acquisitions included TheraSense ($1.2 billion) and i-STAT ($394 million) in 2004. These contributed to a $232 million charge for acquired in-process research and development (IPR&D) for the nine months.
• Discontinued Operations: The spin-off of Hospira resulted in $60.0 million of net earnings from discontinued operations for the nine months ended September 30, 2004, compared to $198.4 million in the prior year (which included a full nine months of Hospira operations).
• Segment Performance: Pharmaceutical Products sales grew 15.7% (nine months), driven by Humira, Tricor, Flomax, and Mobic. Diagnostic Products grew 9.7%, aided by the TheraSense acquisition. International sales grew 15.9%.
• Expenses: Selling, general, and administrative (SG&A) expenses decreased 1.8% for the nine months, largely due to a $614 million one-time charge in the second quarter of 2003 related to the Ross enteral nutrition investigation settlement.

Guidance, Outlook, and Risks

• Guidance: Management confirmed its earnings per share guidance provided in the third-quarter earnings release, expecting favorable trends to offset a potential $40 million reduction in income from the TAP Pharmaceutical joint venture due to a Lupron settlement and reduced Prevacid purchases.
• Product Outlook: Worldwide sales of Humira are forecasted to exceed $800 million for the full year 2004 and $1.2 billion in 2005.
• Liquidity: The company maintains strong liquidity with $3.0 billion in unused lines of credit and a long-term debt rating of AA (S&P) and A1 (Moody's). Net cash from operating activities is expected to continue to exceed capital expenditures and dividends.
• Legal and Regulatory Risks:
  • Antitrust: Ongoing investigations and suits regarding prescription drug pricing and patent settlements (e.g., Hytrin, Lupron). Abbott estimates a potential loss range of $130 million to $225 million for legal and environmental matters, with $160 million currently reserved.
  • Generic Competition: FDA approval for generic Synthroid in Q2 2004 has introduced competition, though sales remained strong in the first nine months.
  • Legislation: The American Jobs Creation Act of 2004 may impact tax rates if foreign earnings are remitted. Changes to Medicare reimbursement formulas effective January 1, 2005, present uncertainty.
• Capital Allocation: The company completed a 25 million share repurchase program in Q3 2004 and authorized a new 50 million share repurchase program in October 2004.

Investor Verification Checklist

• Spin-off Accounting: Verify the treatment of Hospira as discontinued operations and the specific assets/liabilities retained by Abbott versus transferred to Hospira.
• Acquisition Impact: Assess the integration costs and amortization schedules for TheraSense and i-STAT, which significantly impacted IPR&D charges and intangible assets.
• TAP Joint Venture: Monitor the final court approval of the Lupron settlement and the impact on Abbott's share of TAP income.
• Generic Competition: Track the erosion of Synthroid sales following the entry of generic competitors in Q2 2004.
• Legal Reserves: Review the adequacy of the $160 million reserve against the estimated $130 million to $225 million potential loss range for antitrust and environmental matters.
• Currency Effects: Analyze the sensitivity of future results to exchange rate fluctuations, given the significant contribution of the weaker dollar to 2004 sales growth.